TG Therapeutics, Inc. (TGTX)
| Market Cap | 5.69B |
| Revenue (ttm) | 152,000 |
| Net Income (ttm) | -279.38M |
| Shares Out | 115.33M |
| EPS (ttm) | -2.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $40.20 |
| Previous Close | $39.85 |
| Change ($) | 0.35 |
| Change (%) | 0.88% |
| Day's Open | 40.33 |
| Day's Range | 39.82 - 40.94 |
| Day's Volume | 1,030,372 |
| 52-Week Range | 16.56 - 56.74 |
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET Fireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET
ULTRA-V Phase 2 trial has reached completion of patient enrollment ULTRA-V Phase 2 trial has reached completion of patient enrollment
Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions
Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ET Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ET
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and ...
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Compan...
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company's novel, glycoen...
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -24.56% and -5.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of final results from the Phase 3 GENUINE trial evaluating ublituximab, the Company's inv...
Large biotechs are taking over small-cap companies (and their cancer treatments) left and right. Could this business be the next target?
UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen
Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET
TG Therapeutics CEO on developing treatments for patients with multiple sclerosis
TG Therapeutics CEO Mike Weiss explained the biopharmaceutical company's plans to address the multiple sclerosis drug market and carve a lane away from competitors in the space.
Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET
After a protracted wait, TG Therapeutics Inc. (NASDAQ:TGTX) shareholders finally got rewarded for their patience last month when the stock began a rapid climb to its current price of $52. That's a gain ...
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
These biotech stocks could sink or soar following some important approval decisions slated for the new year.
Umbralisib and ublituximab have excellent chances of gaining FDA approval for various blood cancers next year. TGTX also recently reported robust data for ublituximab as a treatment for relapsing multip...
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today annou...
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeuti...
TG Therapeutics stock jumped after the biotech firm announced positive top-line results from two phase 3 studies for its Ublituximab treatment of multiple sclerosis patients. The post TG Therapeutics St...
Both studies met their primary endpoint of significantly reducing annualized relapse rate ( ARR ) (p
Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, recently disclosed the firm's portfolio changes for the third quarter of 2020, which ended on Sept. 30.
UNITY-CLL: U2 significantly improved progression-free survival over obin utuz u mab plus chlorambucil (HR= 0 .54, p
U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients achieving undetectable MRD in the peripheral blood and 77% achieving undetectable MRD in bone marrow
Since last year, TGTX has executed its programs brilliantly. Cash position also is decent, although I expect some justified dilution before revenue generation.
NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of data from a Phase 2 study evaluating umbralisib, the Company's investigational once da...
Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET Fireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET
Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 823 active prominent money managers and analyze their ...
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -78.05% and -5.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR= 0 .54, p
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the combination o...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss, the Company’s Execut...
TG Therapeutics (NASDAQ: TGTX) shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients with the pr...
NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA)...
TG Therapeutics (TGTX) CEO, Michael Weiss on Q2 2020 Results - Earnings Call Transcript
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and -5.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developments.
Does TG Therapeutics (TGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbralisib, the C...
NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced the compl...
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymph... [Read more...]
| Industry Biotechnology | IPO Date Dec 14, 1995 |
| CEO Michael Weiss | Employees 272 |
| Stock Exchange NASDAQ | Ticker Symbol TGTX |
Financial Performance
In 2020, TGTX's revenue was $152,000, a change of 0.00% compared to the previous year's $152,000. Losses were -$279.38 million, 61.6% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is 73.14, which is an increase of 81.94% from the latest price.